Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets

Thrombosis and Haemostasis

Volumn 88, Issue 6, 2002, Pages 1039-1046

  Alimardani, Gulie ^a,b   Guichard, Josette ^a   Fichelson, Serge ^a   Cramer, Elisabeth M ^a,c  

^a INSTITUT COCHIN   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c HÔPITAL AMBROISE PARÉ   (France)

Author keywords

GPIb; Megakaryocytes; Platelets

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; CD34 ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; GLYCOPROTEIN IB ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY SZ1; MONOCLONAL ANTIBODY SZ2; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEGAKARYOCYTE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE DISORDER; THROMBOCYTE RELEASE REACTION;

EID: 0036917764     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613352     Document Type: Article

References (38)

1. Andrews RK, Lopez JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 1997; 29: 91-105.
2. Lopez JA. The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinolysis 1994; 5: 97-119.
3. Lopez JA, Dong JF. Structure and function of the glycoprotein Ib-IX-V complex. Curr Opin Hematol 1997; 4: 323-9.
4. Debili N, Kieffer N, Nakazawa M, Guichard J, Titeux M, Cramer E, Breton-Gorius J, Vainchenker W. Expression of platelet glycoprotein Ib by cultured human megakaryocytes: Ultrastructural localization and biosynthesis. Blood 1990; 76: 368-76.
5. Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, Lopez JA. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192: 193-204.
6. Cauwenberghs N, Meiring M, Vauterin S, Van Wyk V, Lamprecht S, Roodt JP, Novak L, Harsfalvi J, Deckmyn H, Kotze HF. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000; 20: 1347-53.
7. Cadroy Y, Hanson SR, Kelly AB, Marzec UM, Evatt BL, Kunicki TJ, Montgomery RR, Harker LA. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 1994; 83: 3218-24.
8. Kiefel V, Santoso S, Kaufmann E, Mueller-Eckhardt C. Autoantibodies against platelet glycoprotein Ib/IX: A frequent finding in autoimmune thrombocytopenic purpura. Br J Haematol 1991; 79: 256-62.
9. McMillan R, Tani P, Millard F, Berchtold P, Renshaw L, Woods VL, Jr., Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP. Blood 1987; 70: 1040-5.
10. Szatkowski NS, Kunicki TJ, Aster RH. Identification of glycoprotein Ib as a target for autoantibody in idiopathic (autoimmune) thrombocytopenic purpura. Blood 1986; 67: 310-5.
11. Woods VL, Jr., Kurata Y, Montgomery RR, Tani P, Mason D, Oh EH, McMillan R. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 1984; 64: 156-60.
12. McMillan R. The pathogenesis of chronic immune (idiopathic) thrombocytopenic purpura. Semin Hematol 2000; 37: 5-9.
13. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: Their clinical significance and response to treatment. Blood 1993; 81: 1246-50.
14. Suvajdzic N, Rolovic Z, Elezovic I, Colovic M. Megakaryocytopoiesis in refractory chronic immune thrombocytopenia. Hematol Cell Ther 1999; 41: 163-8.
15. Wang ZY, Shen ZX. Megakaryocytes and platelets in immune thrombocytopenic purpura. Baillieres Clin Haematol 1997; 10: 89-107.
16. He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood 1994; 83: 1024-32.
17. Beardsley DS, Estem M. Platelet autoantibodies in immune thrombocytopenic purpura. Transfus Sci 1998; 19: 237-44.
18. Berchtold P, Muller D, Beardsley D, Fujisawa K, Kaplan C, Kekomaki R, Lipp E, Morell-Kopp MC, Kiefel V, McMillan R, Von Dem Borne AE, Imbach P. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol 1997; 96: 477-83.
19. Chong BH, Keng TB. Advances in the diagnosis of idiopathic thrombocytopenic purpura. Semin Hematol 2000; 37: 249-60.
20. Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999; 104: 442-7.
21. Hou M, Stockelberg D, Kutti J, Wadenvik H. Antibodies against platelet GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 1995; 55: 307-14.
22. Nomura S, Yanabu M, Soga T, Kido H, Fukuroi T, Yamaguchi K, Nagata H, Kokawa T, Yasunaga K. Analysis of idiopathic thrombocytopenic purpura patients with antiglycoprotein IIb/IIIa or Ib autoantibodies. Acta Haematol 1991; 86: 25-30.
23. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Haematol 2000; 37: 239-48.
24. Mehta YS, Pathare AV, Badakere SS, Ghosh K, Mohanty D. Influence of auto-antibody specificities on the clinical course in patients with chronic and acute ITP. Platelets 2000; 11: 94-98.
25. Hagberg IA, Lyberg T. Blood platelet activation evaluated by flow cytometry: Optimised methods for clinical studies. Platelets 200; 11: 137-50.
26. Cramer EM, Caen JP, Drouet L, Breton-Gorius J. Absence of tubular structures and immunolabeling for von Willebrand factor in the platelet alpha-granules from porcine von Willebrand disease. Blood 1986; 68: 774-8.
27. Cramer EM, Meyer D, Le Menn R, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood 1985; 66: 710-3.
28. Cramer EM, Norol F, Guichard J, Breton-Gorius J, Vainchenker W, Masse JM, Debili N. Ultrastructure of platelet formation by human megakaryocytes cultured with the Mpl ligand. Blood 1997; 89: 2336-46.
29. Vitrat N, Cohen-Solal K, Norol F, Guichard J, Cramer E, Vainchenker W, Wendling F, Debili N. Compared effects of Mpl ligand and other cytokines on human MK differentiation. Stem Cells 1998; 2: 37-51.
30. Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999; 93: 1951-8.
31. Berndt MC, Du XP, Booth WJ. Ristocetin-dependent reconstitution of binding of von Willebrand factor to purified human platelet membrane glycoprotein Ib-IX complex. Biochemistry 1988; 27: 633-40.
32. Williamson D, Giuliano S, Jackson SP. Platelet adhesion receptors: Novel targets for anti-thrombotic therapy. Aust N Z J Med 1999; 29: 452-61.
33. Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199-209.
34. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: Platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-8.
35. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000; 35: 915-21.
36. Hayes R, Chesebro JH, Fuster V, Dangas G, Fallon JT, Sharma SK, Coller BS, Badimon L, Marmur JD, Badimon JJ. Antithrombotic effects of abciximab. Am J Cardiol 2000; 85: 1167-72.
37. Chang MC, Lin HK, Peng HC, Huang TF. Antithrombotic effect of crotalin, a platelet membrane glycoprotein Ib antagonist from venom of Crotalus atrox. Blood 1998; 91: 1582-9.
38. Yeh CH, Chang MC, Peng HC, Huang TF. Pharmacological characterization and antithrombotic effect of agkistin, a platelet glycoprotein Ib antagonist. Br J Pharmacol 2001; 132 843-50.